{{Rsnum
|rsid=532545
|Gene=CDA
|Chromosome=1
|position=20588679
|Orientation=minus
|GMAF=0.2057
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CDA
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 8.8 | 43.4 | 47.8
| HCB | 1.5 | 19.0 | 79.6
| JPT | 2.7 | 39.8 | 57.5
| YRI | 0.0 | 7.5 | 92.5
| ASW | 1.8 | 12.3 | 86.0
| CHB | 1.5 | 19.0 | 79.6
| CHD | 1.8 | 17.4 | 80.7
| GIH | 5.9 | 35.6 | 58.4
| LWK | 0.0 | 13.6 | 86.4
| MEX | 3.4 | 51.7 | 44.8
| MKK | 2.6 | 28.8 | 68.6
| TSI | 11.8 | 52.0 | 36.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs532545
|Name_s=CDA: promoter -451C>T
|Gene_s=CDA
|Feature=Intron
|Evidence=PubMed ID:19458626
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: In AML patients receiving cytarabine, the TT genotype for rs532545 was associated with decreased 5-year overall survival (13%) relative to the CC genotype (25%) (p = 0.05), and significantly higher lactate dehydrogenase levels relative to the CC and CT genotypes (p = 0.01). Patients with the TT genotype had greater than 50% increased risk for death compared with patients with the CC genotype (HR = 1.56, p = 0.02). Study size: 360. Study population/ethnicity: AML patients. /Caucasian Germans. Significance metric(s): Type of association: GN; CO; PD; TOX; ADR
|Drugs=cytarabine; daunorubicin
|Drug Classes=
|Diseases=Leukemia, Myeloid, Acute
|Curation Level=Curated
|PharmGKB Accession ID=PA165109669
}}

{{PMID Auto
|PMID=21325291
|Title=A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs532545
|overall_frequency_n=28
|overall_frequency_d=128
|overall_frequency=0.21875
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=23
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}